OTCMKTS:BCTXF BriaCell Therapeutics (BCTXF) Stock Price, News & Analysis $0.39 +0.02 (+4.23%) As of 01/21/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlines About BriaCell Therapeutics Stock (OTCMKTS:BCTXF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BriaCell Therapeutics alerts:Sign Up Key Stats Today's Range$0.38▼$0.4050-Day Range$0.38▼$1.1952-Week Range$3.25▼$17.50Volume446,308 shsAverage Volume1,859 shsMarket Capitalization$304,168.00P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewBriaCell Therapeutics Corp. operates as a clinical-stage biotechnology company that specializes in immunotherapy for advanced breast cancer. It is advancing its targeted immunotherapy program by conducting a Phase I/IIA clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor and a companion diagnostic test, BriaDx, to identify patients to benefit from Bria-IMT. The company was founded by Charles L. Wiseman and Isaac B. Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.Read More… Receive BCTXF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BriaCell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BCTXF Stock News HeadlinesBriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025January 3, 2025 | globenewswire.comBriaCell Announces Proposed Effective Date of Share ConsolidationJanuary 3, 2025 | globenewswire.comKamala’s final humiliation Now, for the first time, I’m going to share these ten investments publicly – the same ones I’ve discussed behind closed doors with some of America’s savviest investors. The obscure, little-known companies we believe could 5x, even 10x, under Trump’s second term…January 22, 2025 | Porter & Company (Ad)Insider Purchases Worth US$5.52m See Losses As BriaCell Therapeutics Market Value Drops To CA$40mDecember 19, 2024 | finance.yahoo.comBriaCell Therapeutics Reports Quarterly Financial LossDecember 17, 2024 | markets.businessinsider.comPromising Phase 2 Results and Safety Profile Justify Buy Rating for BriaCell TherapeuticsDecember 12, 2024 | markets.businessinsider.comBriaCell Prices 7.4 Mln Public Offering, To Raise $5.5 MlnDecember 12, 2024 | markets.businessinsider.comBriaCell Therapeutics: Promising Developments in Cancer Treatment and Positive OutlookDecember 3, 2024 | markets.businessinsider.comSee More Headlines BCTXF Stock Analysis - Frequently Asked Questions How have BCTXF shares performed this year? BriaCell Therapeutics' stock was trading at $0.5558 on January 1st, 2025. Since then, BCTXF shares have decreased by 29.1% and is now trading at $0.3940. View the best growth stocks for 2025 here. How do I buy shares of BriaCell Therapeutics? Shares of BCTXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:BCTXF CUSIPN/A CIKN/A Webwww.briacell.com Phone(604) 921-1810FaxN/AEmployees8Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,680,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-786.77% Debt Debt-to-Equity RatioN/A Current Ratio0.07 Quick Ratio0.07 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($4.55) per share Price / Book-0.09Miscellaneous Outstanding Shares772,000Free FloatN/AMarket Cap$304,168.00 OptionableNot Optionable Beta1.09 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (OTCMKTS:BCTXF) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredKamala’s final humiliation Now, for the first time, I’m going to share these ten investments publicly – the same ones I’ve discussed behi...Porter & Company | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BriaCell Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share BriaCell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
